As the healthcare industry moves toward value-based care, payers are increasingly concerned with clinical outcomes. Health plans are finding that they need to leverage all clinical and administrative data, in addition to claims data, to improve member health and optimize reimbursement within value-based payment models. Harmonizing data across the healthcare continuum presents a significant challenge due to the variety of disconnected data elements that must be connected to get a true 360-degree view of member health. Before healthcare organizations can effectively benefit from the data’s value, the data itself needs to be normalized to achieve semantic interoperability.
The Center for Digital Education (CDE) hosted “Future-Ready Learning: How Technology and Simulation Are Transforming Healthcare Education.” This webinar looked at the ways that healthcare simulation solutions are being applied to give competitive advantage to the colleges, universities and teaching hospitals that adopt them.
This CLE webinar will provide compliance and valuation guidance to counsel for hospitals and physician groups seeking to maximize their relationship, through varied types of professional services agreements (PSAs) in lieu of traditional employment models. There are shifting considerations and trends in today’s healthcare market, as hospitals and physician groups reevaluate the benefits and risks of different engagement models.
Small cell lung cancer (SCLC) is aggressive and often difficult to treat, but many patients may have new hope. On August 17, 2018, the FDA approved the first immunotherapy the checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb for patients with small cell lung cancer. Since this approval, there has been renewed focus on how to make different immunotherapies work for a disease which typicallly comprises 10-15% of all lung cancer cases. In this webinar for patients and caregivers, Matthew Hellmann, M.D., of Memorial Sloan Kettering Cancer Center discusses the new FDA approval, clinical trials, and potential treatments for patients with small cell lung cancer.